Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
12.44
+0.08 (0.65%)
Apr 26, 2024, 11:59 AM EDT - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for TRDA stock have an average target of 21, with a low estimate of 20 and a high estimate of 22. The average target predicts an increase of 68.81% from the current stock price of 12.44.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2024.
Analyst Ratings
The average analyst rating for TRDA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +60.77% | Mar 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $22 | Buy | Initiates | $22 | +76.85% | Jan 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $25 → $20 | Strong Buy | Maintains | $25 → $20 | +60.77% | Nov 27, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +100.96% | Sep 22, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +100.96% | Aug 9, 2023 |
Financial Forecast
Revenue This Year
78.93M
from 129.01M
Decreased by -38.82%
Revenue Next Year
38.94M
from 78.93M
Decreased by -50.66%
EPS This Year
-2.55
from -0.20
EPS Next Year
-3.54
from -2.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 136.5M | 59.2M | 59.2M | 14.8M | n/a |
| Avg | 78.9M | 38.9M | 42.3M | 7.2M | n/a |
| Low | 42.2M | 14.7M | 24.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.8% | -24.9% | 52.1% | -65.0% | - |
| Avg | -38.8% | -50.7% | 8.7% | -83.0% | - |
| Low | -67.3% | -81.4% | -37.1% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.15 | -2.87 | -2.92 | -4.03 |
| Avg | -2.55 | -3.54 | -3.42 | -3.92 |
| Low | -4.46 | -4.21 | -4.31 | -3.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.